Antidepressant Labeling Should Reflect Negative Pediatric Studies
This article was originally published in The Pink Sheet Daily
With study results for several drugs failing to show pediatric efficacy, an FDA advisory committee suggests revising a standard labeling statement that efficacy "has not been established" in children. The committee also recommends that labeling highlight the need for suicide monitoring.
You may also be interested in...
Joint session with Psychopharmacologic Advisory Committee will be new cross-center committee's first meeting.
A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability